GET DAILY SIGNALSSkye Bioscience (SKYE) Stock Falls -40% Over 30 Days on Strategic and Compliance Pressures
Key Takeaways
- SKYE fell roughly 40% over the last 30 days, declining from about $1.53 per share to approximately $0.92.
- The decline extends a longer slide: the stock is down roughly 79% over the past three months from about $4.33 in mid-August.
- Key pressures include the discontinuation of the legacy nimacimab obesity program, Nasdaq listing-compliance concerns, and heavy dilution tied to the proposed Redx Pharma transaction.
- A unanimous jury verdict in Skye's favor in a whistleblower and retaliation lawsuit helped fuel a partial rebound from near $0.51 in early November.
- The proposed Redx Pharma reverse merger would create a fibrosis-focused company called Fibrx Therapeutics, with existing Skye shareholders holding a small minority stake.
Skye Bioscience (SKYE) Background and Recent Pivot
SKYE is a clinical-stage biopharmaceutical company based in San Diego that develops molecules modulating G-protein-coupled receptors to address obesity, overweight, and related metabolic conditions. Its lead asset had been nimacimab, a peripherally-restricted negative allosteric modulating antibody aimed at the cannabinoid receptor 1. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Investors had followed the name for its place in the metabolic space, yet after the Phase 2a monotherapy trial missed its primary weight-loss endpoint, the company announced an agreement to be acquired by Redx Pharma Limited in a reverse-merger structure. The combined entity would shift focus toward fibrosis.
Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, SKYE declined approximately 40%, moving from a closing level of about $1.53 to roughly $0.92 per share. The period included sharp intraday swings in early November, with the stock touching about $0.51 before a partial recovery on heavier volume.
This 30-day move fits into a steeper downtrend. Three months earlier the shares traded near $4.33, so the quarterly decline comes to roughly 79%. The price now sits well below its 52-week high near $12.72. From what I see, the trend has been consistently negative.
Drivers Behind the Recent 30-Day Move
Several factors converged to weigh on the shares. The company released its third-quarter 2026 results in early November, underscoring ongoing operating losses and cash burn at a pre-revenue clinical-stage firm. Nasdaq listing-compliance risks also surfaced after shareholders’ equity fell below the exchange’s minimum threshold. In addition, the legacy nimacimab program was wound down following the Phase 2a monotherapy miss.
The proposed Redx Pharma reverse merger introduced further pressure because existing Skye stockholders would retain only a small minority stake in the combined company. In early November the stock dropped sharply over several days, then recovered somewhat after Skye reported a unanimous jury verdict in its favor in the Wendy Cunning whistleblower and retaliation lawsuit.
What Shaped Performance Across the Full Quarter
The broader quarterly decline was driven largely by the August 14, 2026 announcement of the transaction agreement with Redx Pharma and related financings totaling $125 million. The deal would create a fibrosis-focused entity operating as Fibrx Therapeutics under Redx’s management team, marking a clear departure from the prior metabolic-disease emphasis and raising dilution concerns for legacy holders.
This pivot followed the CBeyond Phase 2a study disappointment, in which nimacimab monotherapy failed to show statistically significant weight loss versus placebo, although combination data with semaglutide indicated an add-on benefit. The combination of the failed readout, program discontinuation, exchange compliance issues, and continued losses created a persistent overhang throughout the quarter. I reviewed the price action with Tickeron’s AI Trend Prediction Engine to gauge potential movements.
Key Items to Watch Going Forward
Looking ahead, the outcome of the stockholder vote on the Redx Pharma transaction, along with closing timing and final terms, will be central. Nasdaq compliance efforts, including any plan to regain the minimum shareholders’ equity requirement and the possibility of a reverse stock split or delisting, also merit attention. Other items include post-trial motions or appeals in the Cunning litigation, the company’s cash position, and further details on the combined fibrosis pipeline. Clinical-stage micro-cap biotechs carry elevated risk, and execution of the strategic transition will shape sentiment.
Using AI Tools in My Research Process
One resource I turn to when assessing situations like this is Tickeron’s AI Trading Bots. The platform lets me review and backtest a range of algorithmic strategies across different timeframes and risk profiles, which helps complement my own fundamental review without replacing it. Investors interested in data-driven approaches may find the curated options worth exploring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SKYE turns negative, indicating new downward trend
SKYE saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 87 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SKYE turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 37 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SKYE entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SKYE's RSI Indicator exited the oversold zone, 34 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +33.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in 197 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SKYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.817) is normal, around the industry mean (3.498). P/E Ratio (-0.097) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SKYE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement